elvitegravir: Clinical Trials

18 trials of elvitegravir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 2 terminated, 2 unknown, 2 withdrawn. 6 Phase 4, 3 Phase 2, 2 Not applicable, 2 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 46Completed 4, Unknown 1, Withdrawn 1
Phase 23Completed 2, Terminated 1
Not applicable2Completed 1, Withdrawn 1
Phase 12Completed 2
Phase 32Completed 1, Terminated 1

Follow elvitegravir: new trials by email Literature Review of elvitegravir trials Research Report on elvitegravir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Research on the Psychological Status of Patients With HIV-1 Infection
All kinds of INSTI medications, All kinds of conventional medications - HIV-1-infection, Anxiety Depression
Not yet recruitingShanxi Bethune Hospital5002025-08-012025-07-23
Analysis of Crushed and Whole Tablet Genvoya
Genvoya Oral dose, Genvoya Crushed Dose - Healthy Volunteers
Phase 4CompletedJohns Hopkins University122019-04-152023-01-31
Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting
prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir - HIV
TerminatedFondation Ophtalmologique Adolphe de Rothschild12018-11-192020-02-27
Same-Day Treatment With Genvoya vs. EFV/TDF/3TC
Elvitegravir, Cobicistat, TAF, FTC, Efavirenz, TDF, and 3TC - HIV/AIDS
Not applicableWithdrawnHaitian Group for the Study of Kaposi's Sarcoma and Opportunistic2018-05-012020-03-18
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection
Elvitegravir/Cobicistat/Emtricitabine - Chronic Hepatitis B in HIV Patient, Kidney Injury
UnknownNational Taiwan University Hospital2752018-02-062019-08-28
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
Genvoya, Epclusa, Biktarvy - HIV-1-infection, Hepatitis C, Chronic
Phase 4UnknownSaskatchewan Health Authority - Regina Area252018-02-012019-12-24
Early ART to Limit Infection and Establishment of Reservoir
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy - HIV-1 Infection
Phase 2CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections1952017-01-242025-08-29
Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.
Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra), elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil - HIV
Phase 4CompletedFundacion Clinic per a la Recerca Biomédica1602015-06-062017-02-23
Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC, Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC, Darunavir - Healthy
Phase 1CompletedJanssen Sciences Ireland UC722015-06-012017-10-17
Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive
elvitegravir/cobicistat/emtricitabine/tenofovir, Darunavir, abacavir/lamivudine - Patient Compliance, Antiretroviral Therapy Intolerance
Phase 4WithdrawnJuan A. Arnaiz2015-06-012025-07-30
Renal Integrase Study
Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat), Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet, Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir) - HIV
Phase 4CompletedSt Stephens Aids Trust602015-03-012017-06-27
SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers
Dolutegravir, Elvitegravir and Cobicistat - HIV
Phase 1CompletedSt Stephens Aids Trust172014-10-012016-08-15
An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks - HIV-2 Infection
Phase 4CompletedUniversity of Washington302014-09-012018-07-26
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir) - HIV Disease
Not applicableCompletedMassachusetts General Hospital102014-01-012017-07-28
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants
EVG, Background regimen - Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Phase 2 / Phase 3TerminatedGilead Sciences312013-08-262018-08-09
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
Elvitegravir, Raltegravir, EVG placebo - HIV Infection
Phase 3CompletedGilead Sciences7242008-07-012016-05-30
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
EVG, RTV, ARV regimen - HIV Infections
Phase 2CompletedGilead Sciences1922007-02-012016-04-25
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2 - HIV Infections
CompletedNational Institute of Allergy and Infectious Diseases (NIAID)15782003-06-092025-12-02

Conditions studied

Acquired Immunodeficiency Syndrome (6)  ·  HIV Infections (4)  ·  Bone Diseases (1)  ·  Bone Diseases, Metabolic (1)  ·  Coinfection (1)  ·  Hepatitis C (1)  ·  Hepatitis C, Chronic (1)  ·  Opioid-Related Disorders (1)  ·  Patient Compliance (1)

Sponsors

Gilead Sciences (3)  ·  St Stephens Aids Trust (2)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1)  ·  Fondation Ophtalmologique Adolphe de Rothschild (1)  ·  Fundacion Clinic per a la Recerca Biomédica (1)  ·  Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic (1)  ·  Janssen Sciences Ireland UC (1)  ·  Johns Hopkins University (1)  ·  Juan A. Arnaiz (1)  ·  Massachusetts General Hospital (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  National Taiwan University Hospital (1)  ·  Saskatchewan Health Authority - Regina Area (1)  ·  Shanxi Bethune Hospital (1)  ·  University of Washington (1)

Countries

United States (7)  ·  Puerto Rico (3)  ·  Spain (3)  ·  Thailand (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Brazil (2)  ·  Canada (2)  ·  France (2)  ·  Italy (2)  ·  South Africa (2)  ·  Argentina (1)  ·  Australia (1)  ·  Botswana (1)  ·  Germany (1)

Top investigators

Alexander Wong, MD (1)  ·  Chien-Ching Hung (1)  ·  Craig Hendrix, MD (1)  ·  Geoffrey S Gottlieb, MD PhD (1)  ·  Graeme Moyle, MD, MBBS, Dip GUN (1)  ·  Javier Szwarcberg, MD, MPH (1)  ·  Jean W Pape, MD (1)  ·  Mark Mirochnick, MD (1)  ·  Martin Rhee, MD (1)  ·  Moussa Seydi, MD (1)

Results publications

PMID 16470119, PMID 16988514, PMID 18366444, PMID 18795962, PMID 18989231, PMID 20002783, PMID 20632458, PMID 21283017, PMID 22015077, PMID 22083071, PMID 22129166, PMID 23305215, PMID 23392467, PMID 25162818, PMID 25261418, PMID 25407158, PMID 25950206, PMID 25959631, PMID 26202768, PMID 26918544, PMID 27540363, PMID 29369162, PMID 29520730, PMID 29528944, PMID 29672676, PMID 30134297, PMID 30358179, PMID 30412360, PMID 30530925, PMID 30715324, PMID 31489678, PMID 32015036, PMID 32451908, PMID 33252495, PMID 33273214, PMID 33318014, PMID 33382405, PMID 33540057, PMID 34076612, PMID 34732682, PMID 36301928, PMID 40741959, PMID 42828638

NIH funding

2014 (1), 2015 (1), 2UM1AI068636 (1)